• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病理学家在新辅助治疗乳腺癌管理中不断演变的角色:基于西班牙临床经验的建议。

The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.

机构信息

Servicio de Anatomía Patológica, Hospital Clínico Universitario, Avda. Blasco Ibáñez, 17, 46010, Valencia, Spain.

Servicio de Anatomía Patológica, Hospital Virgen Del Rocío, Seville, Spain.

出版信息

Clin Transl Oncol. 2018 Mar;20(3):382-391. doi: 10.1007/s12094-017-1725-z. Epub 2017 Aug 9.

DOI:10.1007/s12094-017-1725-z
PMID:28795336
Abstract

PURPOSE

To compare the current international standards for neoadjuvant systemic therapy (NAST) protocols, and establish consensus recommendations by Spanish breast pathologists; and to look into the Spanish reality of defining pathological complete response in daily practice.

MATERIALS AND METHODS

A modified Delphi technique was used to gain consensus among a panel of 46 experts with regard to important issues about NAST specimens, with the objective of standardize handling and analysis of these breast cancer specimens. In addition, a survey was conducted among 174 pathologists to explore the Spanish reality of post-NAST breast cancer specimens handling.

RESULTS

Our survey shows that pathologists in Spain follow the same guidelines as their international colleagues and face the same problems and controversies. Among the experts, 94.1% agreed on the recommendation for a pre-treatment evaluation with a core needle biopsy, and 100% of experts agreed on the need of having properly indicated information for the post-NAST surgical specimens. However, only 82.7% of them receive properly labelled specimens and even less receive specimens where markers are identified and the degree of clinical/radiological response is mentioned. Among participants 59.9% were familiar with the residual cancer burden system for post-NAST response quantification, but only 16.1% used it regularly.

CONCLUSIONS

Active participation on breast cancer multidisciplinary teams, optimal usage of core needle biopsy for timely and standardized procedures for the diagnostic analysis, and accurate diagnosis of pathological complete response and complete evaluation of the response to NAST need to become the standard practice when handling breast cancer specimens in Spain.

摘要

目的

比较新辅助全身治疗(NAST)方案的现行国际标准,并由西班牙乳腺病理学家达成共识建议;并研究西班牙在日常实践中定义病理完全缓解的现状。

材料和方法

采用改良 Delphi 技术,就 NAST 标本的重要问题达成了 46 名专家小组的共识,旨在规范这些乳腺癌标本的处理和分析。此外,对 174 名病理学家进行了一项调查,以了解西班牙处理 NAST 后乳腺癌标本的实际情况。

结果

我们的调查显示,西班牙的病理学家遵循与国际同行相同的指南,并面临着相同的问题和争议。在专家中,94.1% 同意推荐进行术前评估的核心针活检,100% 的专家同意需要为 NAST 后手术标本提供适当的指示信息。然而,只有 82.7% 的人收到了适当标记的标本,甚至更少的人收到了标记有肿瘤残留程度的临床/放射学反应的标本。在参与者中,59.9% 的人熟悉 NAST 后反应定量的残留癌负荷系统,但只有 16.1% 的人经常使用它。

结论

积极参与乳腺癌多学科团队,优化使用核心针活检,及时进行标准化的诊断分析程序,准确诊断病理完全缓解,并全面评估 NAST 的反应,应成为西班牙处理乳腺癌标本的标准做法。

相似文献

1
The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.病理学家在新辅助治疗乳腺癌管理中不断演变的角色:基于西班牙临床经验的建议。
Clin Transl Oncol. 2018 Mar;20(3):382-391. doi: 10.1007/s12094-017-1725-z. Epub 2017 Aug 9.
2
A survey of Australian and New Zealand clinical practice with neoadjuvant systemic therapy for breast cancer.澳大利亚和新西兰乳腺癌新辅助全身治疗临床实践调查。
Intern Med J. 2016 Jun;46(6):677-83. doi: 10.1111/imj.13049.
3
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.乳腺癌新辅助治疗后标本临床研究中病理评估和报告的标准化:国际工作组的建议。
Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24.
4
Breast Specimen Processing and Reporting With an Emphasis on Margin Evaluation: A College of American Pathologists Survey of 866 Laboratories.乳腺标本处理和报告,重点评估切缘:美国病理学家学院对 866 家实验室的调查。
Arch Pathol Lab Med. 2018 Apr;142(4):496-506. doi: 10.5858/arpa.2016-0626-CP. Epub 2018 Jan 12.
5
The Perfect Pathology Report After Neoadjuvant Therapy.新辅助治疗后的完美病理报告。
J Natl Cancer Inst Monogr. 2015 May;2015(51):47-50. doi: 10.1093/jncimonographs/lgv016.
6
Lack of Standardization in the Processing and Reporting of Post-Neoadjuvant Breast Cancer Specimens.新辅助化疗后乳腺癌标本处理和报告缺乏标准化。
Arch Pathol Lab Med. 2020 Oct 1;144(10):1262-1270. doi: 10.5858/arpa.2019-0539-OA.
7
National survey of B1 and B2 reporting of breast needle core biopsies.乳腺针芯活检B1和B2报告的全国性调查。
J Clin Pathol. 2016 Mar;69(3):271-4. doi: 10.1136/jclinpath-2015-203291. Epub 2015 Oct 9.
8
Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.接受新辅助化疗患者的病理学标准化
Ann Surg Oncol. 2016 Oct;23(10):3153-61. doi: 10.1245/s10434-016-5317-x. Epub 2016 Jul 5.
9
Diagnosis and follow-up of patients with Hunter syndrome in Spain: A Delphi consensus.西班牙亨特综合征患者的诊断与随访:德尔菲共识
Medicine (Baltimore). 2018 Jul;97(29):e11246. doi: 10.1097/MD.0000000000011246.
10
Interobserver variability between general and expert pathologists during the histopathological assessment of large-core needle and open biopsies of non-palpable breast lesions.在对不可触及乳腺病变进行粗针穿刺活检和开放活检的组织病理学评估过程中,普通病理学家与专家病理学家之间的观察者间变异性。
Eur J Cancer. 2003 Oct;39(15):2187-91. doi: 10.1016/s0959-8049(03)00540-9.

引用本文的文献

1
Developing consensus in Histopathology: the role of the Delphi method.制定组织病理学共识:德尔菲法的作用。
Histopathology. 2022 Aug;81(2):159-167. doi: 10.1111/his.14650. Epub 2022 Apr 24.
2
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.早期乳腺癌的新辅助治疗:临床与研究立场声明。
Oncologist. 2019 May;24(5):603-611. doi: 10.1634/theoncologist.2018-0228. Epub 2019 Feb 1.

本文引用的文献

1
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.利用生物标志物指导早期浸润性乳腺癌女性辅助性全身治疗决策:美国临床肿瘤学会临床实践指南
J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8.
2
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.乳腺癌新辅助治疗后标本临床研究中病理评估和报告的标准化:国际工作组的建议。
Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24.
3
The Perfect Pathology Report After Neoadjuvant Therapy.
新辅助治疗后的完美病理报告。
J Natl Cancer Inst Monogr. 2015 May;2015(51):47-50. doi: 10.1093/jncimonographs/lgv016.
4
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.BIG-NABCG合作组关于乳腺癌新辅助临床试验中残留病灶标准化病理特征的建议。
Ann Oncol. 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. Epub 2015 May 27.
5
Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.新辅助化疗后乳腺癌预后评估中残余癌负担的可重复性
Mod Pathol. 2015 Jul;28(7):913-20. doi: 10.1038/modpathol.2015.53. Epub 2015 May 1.
6
Standardised method for reporting exercise programmes: protocol for a modified Delphi study.报告锻炼计划的标准化方法:一项改良德尔菲研究的方案
BMJ Open. 2014 Dec 30;4(12):e006682. doi: 10.1136/bmjopen-2014-006682.
7
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.残留增殖性癌负担预测新辅助化疗后的长期结局。
Ann Oncol. 2015 Jan;26(1):75-80. doi: 10.1093/annonc/mdu508. Epub 2014 Oct 30.
8
Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies.定义共识:系统评价为 Delphi 研究报告推荐了方法学标准。
J Clin Epidemiol. 2014 Apr;67(4):401-9. doi: 10.1016/j.jclinepi.2013.12.002.
9
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.乳腺癌的病理完全缓解和长期临床获益:CTNeoBC 汇总分析。
Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14.
10
An international Ki67 reproducibility study.一项国际 Ki67 可重复性研究。
J Natl Cancer Inst. 2013 Dec 18;105(24):1897-906. doi: 10.1093/jnci/djt306. Epub 2013 Nov 7.